A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Inclusion Criteria:

Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer
Participants must have stopped other forms of treatment for the cancer
In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study
Participants must not be pregnant, and must agree to use birth control
Participants must have progressed through or be intolerant to therapies with known clinical benefit

Exclusion Criteria:

Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids
Participant must not have cancer that has spread to the brain
Participant must not have received a vaccine within the last 30 days
Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery
Participant must not have an infection that is currently being treated